Cargando…
Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans
BACKGROUND: Zika virus has recently spread to South- and Central America, causing congenital birth defects and neurological complications. Many people at risk are flavivirus pre-immune due to prior infections with other flaviviruses (e.g. dengue virus) or flavivirus vaccinations. Since pre-existing...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021315/ https://www.ncbi.nlm.nih.gov/pubmed/32017766 http://dx.doi.org/10.1371/journal.pntd.0008034 |
_version_ | 1783497876828061696 |
---|---|
author | Malafa, Stefan Medits, Iris Aberle, Judith H. Aberle, Stephan W. Haslwanter, Denise Tsouchnikas, Georgios Wölfel, Silke Huber, Kristina L. Percivalle, Elena Cherpillod, Pascal Thaler, Melissa Roßbacher, Lena Kundi, Michael Heinz, Franz X. Stiasny, Karin |
author_facet | Malafa, Stefan Medits, Iris Aberle, Judith H. Aberle, Stephan W. Haslwanter, Denise Tsouchnikas, Georgios Wölfel, Silke Huber, Kristina L. Percivalle, Elena Cherpillod, Pascal Thaler, Melissa Roßbacher, Lena Kundi, Michael Heinz, Franz X. Stiasny, Karin |
author_sort | Malafa, Stefan |
collection | PubMed |
description | BACKGROUND: Zika virus has recently spread to South- and Central America, causing congenital birth defects and neurological complications. Many people at risk are flavivirus pre-immune due to prior infections with other flaviviruses (e.g. dengue virus) or flavivirus vaccinations. Since pre-existing cross-reactive immunity can potentially modulate antibody responses to Zika virus infection and may affect the outcome of disease, we analyzed fine-specificity as well as virus-neutralizing and infection-enhancing activities of antibodies induced by a primary Zika virus infection in flavivirus-naïve as well as yellow fever- and/or tick-borne encephalitis-vaccinated individuals. METHODOLOGY: Antibodies in sera from convalescent Zika patients with and without vaccine-induced immunity were assessed by ELISA with respect to Zika virus-specificity and flavivirus cross-reactivity. Functional analyses included virus neutralization and infection-enhancement. The contribution of IgM and cross-reactive antibodies to these properties was determined by depletion experiments. PRINCIPAL FINDINGS: Pre-existing flavivirus immunity had a strong influence on the antibody response in primary Zika virus infections, resulting in higher titers of broadly flavivirus cross-reactive antibodies and slightly lower levels of Zika virus-specific IgM. Antibody-dependent enhancement (ADE) of Zika virus was mediated by sub-neutralizing concentrations of specific IgG but not by cross-reactive antibodies. This effect was potently counteracted by the presence of neutralizing IgM. Broadly cross-reactive antibodies were able to both neutralize and enhance infection of dengue virus but not Zika virus, indicating a different exposure of conserved sequence elements in the two viruses. CONCLUSIONS: Our data point to an important role of flavivirus-specific IgM during the transient early stages of infection, by contributing substantially to neutralization and by counteracting ADE. In addition, our results highlight structural differences between strains of Zika and dengue viruses that are used for analyzing infection-enhancement by cross-reactive antibodies. These findings underscore the possible impact of specific antibody patterns on flavivirus disease and vaccination efficacy. |
format | Online Article Text |
id | pubmed-7021315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-70213152020-02-26 Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans Malafa, Stefan Medits, Iris Aberle, Judith H. Aberle, Stephan W. Haslwanter, Denise Tsouchnikas, Georgios Wölfel, Silke Huber, Kristina L. Percivalle, Elena Cherpillod, Pascal Thaler, Melissa Roßbacher, Lena Kundi, Michael Heinz, Franz X. Stiasny, Karin PLoS Negl Trop Dis Research Article BACKGROUND: Zika virus has recently spread to South- and Central America, causing congenital birth defects and neurological complications. Many people at risk are flavivirus pre-immune due to prior infections with other flaviviruses (e.g. dengue virus) or flavivirus vaccinations. Since pre-existing cross-reactive immunity can potentially modulate antibody responses to Zika virus infection and may affect the outcome of disease, we analyzed fine-specificity as well as virus-neutralizing and infection-enhancing activities of antibodies induced by a primary Zika virus infection in flavivirus-naïve as well as yellow fever- and/or tick-borne encephalitis-vaccinated individuals. METHODOLOGY: Antibodies in sera from convalescent Zika patients with and without vaccine-induced immunity were assessed by ELISA with respect to Zika virus-specificity and flavivirus cross-reactivity. Functional analyses included virus neutralization and infection-enhancement. The contribution of IgM and cross-reactive antibodies to these properties was determined by depletion experiments. PRINCIPAL FINDINGS: Pre-existing flavivirus immunity had a strong influence on the antibody response in primary Zika virus infections, resulting in higher titers of broadly flavivirus cross-reactive antibodies and slightly lower levels of Zika virus-specific IgM. Antibody-dependent enhancement (ADE) of Zika virus was mediated by sub-neutralizing concentrations of specific IgG but not by cross-reactive antibodies. This effect was potently counteracted by the presence of neutralizing IgM. Broadly cross-reactive antibodies were able to both neutralize and enhance infection of dengue virus but not Zika virus, indicating a different exposure of conserved sequence elements in the two viruses. CONCLUSIONS: Our data point to an important role of flavivirus-specific IgM during the transient early stages of infection, by contributing substantially to neutralization and by counteracting ADE. In addition, our results highlight structural differences between strains of Zika and dengue viruses that are used for analyzing infection-enhancement by cross-reactive antibodies. These findings underscore the possible impact of specific antibody patterns on flavivirus disease and vaccination efficacy. Public Library of Science 2020-02-04 /pmc/articles/PMC7021315/ /pubmed/32017766 http://dx.doi.org/10.1371/journal.pntd.0008034 Text en © 2020 Malafa et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Malafa, Stefan Medits, Iris Aberle, Judith H. Aberle, Stephan W. Haslwanter, Denise Tsouchnikas, Georgios Wölfel, Silke Huber, Kristina L. Percivalle, Elena Cherpillod, Pascal Thaler, Melissa Roßbacher, Lena Kundi, Michael Heinz, Franz X. Stiasny, Karin Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans |
title | Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans |
title_full | Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans |
title_fullStr | Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans |
title_full_unstemmed | Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans |
title_short | Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans |
title_sort | impact of flavivirus vaccine-induced immunity on primary zika virus antibody response in humans |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021315/ https://www.ncbi.nlm.nih.gov/pubmed/32017766 http://dx.doi.org/10.1371/journal.pntd.0008034 |
work_keys_str_mv | AT malafastefan impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT meditsiris impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT aberlejudithh impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT aberlestephanw impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT haslwanterdenise impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT tsouchnikasgeorgios impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT wolfelsilke impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT huberkristinal impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT percivalleelena impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT cherpillodpascal impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT thalermelissa impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT roßbacherlena impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT kundimichael impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT heinzfranzx impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans AT stiasnykarin impactofflavivirusvaccineinducedimmunityonprimaryzikavirusantibodyresponseinhumans |